Bayesian variable selection and survival modeling: assessing the Most important comorbidities that impact lung and colorectal cancer survival in Spain

[1]  David Rossell,et al.  Additive Bayesian Variable Selection under Censoring and Misspecification , 2019, Statistical Science.

[2]  J. Bosch-Barrera,et al.  The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study , 2021, BMC Cancer.

[3]  L. Held,et al.  Impact of comorbidities at diagnosis on the 10-year colorectal cancer net survival: A population-based study. , 2021, Cancer epidemiology.

[4]  S. Basu,et al.  Bayesian criterion‐based variable selection , 2021, Journal of the Royal Statistical Society: Series C (Applied Statistics).

[5]  Danilo Alvares,et al.  A tractable Bayesian joint model for longitudinal and survival data , 2021, Statistics in medicine.

[6]  S. Ambs,et al.  How Comorbidities Shape Cancer Biology and Survival. , 2021, Trends in cancer.

[7]  A. Bhattacharya,et al.  Approximate Laplace approximations for scalable model selection , 2020, Journal of the Royal Statistical Society: Series B (Statistical Methodology).

[8]  Danilo Alvares,et al.  Bayesian survival analysis with BUGS , 2020, Statistics in medicine.

[9]  Arcot Sowmya,et al.  A comparison of machine learning methods for survival analysis of high-dimensional clinical data for dementia prediction , 2020, Scientific Reports.

[10]  Jingqin Luo,et al.  Sex differences in cancer mechanisms , 2020, Biology of Sex Differences.

[11]  María-José Sánchez,et al.  Multimorbidity and short-term overall mortality among colorectal cancer patients in Spain: A population-based cohort study. , 2020, European journal of cancer.

[12]  B. Rachet,et al.  Comorbidity prevalence among cancer patients: a population-based cohort study of four cancers , 2020, BMC Cancer.

[13]  P. Lambert,et al.  Marginal measures and causal effects using the relative survival framework , 2020, International journal of epidemiology.

[14]  María-José Sánchez,et al.  Multimorbidity by Patient and Tumor Factors and Time-to-Surgery Among Colorectal Cancer Patients in Spain: A Population-Based Study , 2020, Clinical epidemiology.

[15]  M. Mildner,et al.  Re-epithelialization and immune cell behaviour in an ex vivo human skin model , 2020, Scientific Reports.

[16]  Henrik Singmann,et al.  bridgesampling: An R Package for Estimating Normalizing Constants , 2017, Journal of Statistical Software.

[17]  B. Rachet,et al.  Summarizing and communicating on survival data according to the audience: a tutorial on different measures illustrated with population-based cancer registry data , 2019, Clinical epidemiology.

[18]  O. Aalen,et al.  Limitations of hazard ratios in clinical trials. , 2018, European heart journal.

[19]  Mark F. J. Steel,et al.  Methods and Tools for Bayesian Variable Selection and Model Averaging in Normal Linear Regression , 2018 .

[20]  Stef van Buuren,et al.  Flexible Imputation of Missing Data, Second Edition , 2018 .

[21]  Laurent Remontet,et al.  On a general structure for hazard-based regression models: An application to population-based cancer research , 2018, Statistical methods in medical research.

[22]  Melissa Matz,et al.  Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries , 2018, The Lancet.

[23]  J. Valderas,et al.  Comorbid conditions delay diagnosis of colorectal cancer: a cohort study using electronic primary care records , 2017, British Journal of Cancer.

[24]  Miguel Angel Luque-Fernandez,et al.  Reproducibility, reliability and validity of population-based administrative health data for the assessment of cancer non-related comorbidities , 2017, PloS one.

[25]  R. Weinberg,et al.  Emerging Biological Principles of Metastasis , 2017, Cell.

[26]  Stef van Buuren,et al.  Flexible Imputation of Missing Data , 2012 .

[27]  P. Royston,et al.  The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt , 2011, Statistics in medicine.

[28]  Trevor Hastie,et al.  Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.

[29]  H. Chu,et al.  Survival attributable to an exposure , 2009, Statistics in medicine.

[30]  Haitao Chu,et al.  Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution , 2007, Statistics in medicine.

[31]  James O. Berger,et al.  Posterior model probabilities via path‐based pairwise priors , 2005 .

[32]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[33]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[34]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[35]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[36]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.